Aging
Navigate
Correction|Volume 14, Issue 21|pp 8876—8878

Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma

Dan Zi1,2,3,4,5, Qing Li6,8, Cheng-xiong Xu6,8, Zhi-Wei Zhou7, Guan-Bin Song7, Cheng-Bin Hu9, Fang Wen2, Han-Lin Yang2, Lei Nie2, Xing Zhao3, Jun Tan4, Shu-Feng Zhou5,10, Zhi-Xu He3,11
  • 1Department of Obstetrics and Gynecology, Guizhou Provincial People’s Hospital, Guiyan, Guizhou, 550002, China
  • 2Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China
  • 3Key Laboratory of Adult Stem Cell Transformation Research, Chinese Academy of Medical Sciences/Stem Cell and Tissue Engineering Research Center, Guizhou Medical University, Guiyang, 550004, China
  • 4Key Laboratory of Endemic and Ethnic Diseases and Key Laboratory of Molecular Biology, Ministry of Education, Guizhou Medical University, Guiyang, 550004, China
  • 5Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA
  • 6Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Yuzhon, Chongqing, 40042, China
  • 7Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
  • 8Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400030, China
  • 9Department of Computer Science and Engineering, University of South Florida, Tampa, FL 33620, USA
  • 10Department of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiame, Fujian, 361021, China
  • 11Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China
Received: September 29, 2022Accepted: October 27, 2022Published: November 15, 2022

Copyright: © 2022 Zi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.